- ICH GCP
- 미국 임상 시험 레지스트리
- 임상시험 NCT00562068
Alemtuzumab and Combination Chemotherapy in Treating Patients With Stage I, Stage II, Stage III, or Stage IV Peripheral T-Cell Lymphoma
CHOP-Campath, A Pilot Study of CHOP Plus Campath for the Primary Treatment of ALK-ve Peripheral T Cell Lymphoma [CHOP-CAMPATH]
RATIONALE: Monoclonal antibodies, such as alemtuzumab, can block cancer growth in different ways. Some block the ability of cancer cells to grow and spread. Others find cancer cells and help kill them or carry cancer-killing substances to them. Drugs used in chemotherapy work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from growing. Giving alemtuzumab together with combination chemotherapy may kill more cancer cells.
PURPOSE: This phase I trial is studying the side effects and best dose of alemtuzumab when given together with combination chemotherapy and to see how well it works in treating patients with stage I , stage II , stage III, or stage IV peripheral T-cell lymphoma.
연구 개요
상태
상세 설명
OBJECTIVES:
Primary
- To determine the feasibility of adding alemtuzumab to standard cyclophosphamide, doxorubicin hydrochloride, vincristine, and oral prednisolone (CHOP) chemotherapy in patients with stage I-IV peripheral T-cell lymphoma (PTCL).
- To assess the side effect profile and early and late toxicities of this regimen in a standard dose-escalation design, and to establish an appropriate dose level for future studies.
Secondary
- To document response rates and disease-free survival of patients treated with this regimen, and to compare these findings with those of historical controls.
- To monitor immune reconstitution after therapy.
- To determine the pharmacokinetics of subcutaneous alemtuzumab when given in combination with CHOP chemotherapy.
- To more clearly define the CD52 expression profile in these tumors and to investigate phenotypic variations in PTCL.
- To document changes (if any) in levels of Epstein-Barr virus copy number by polymerase chain reaction during CHOP-alemtuzumab therapy.
OUTLINE: This is a multicenter, dose escalation of alemtuzumab study.
Patients receive CHOP chemotherapy comprising cyclophosphamide IV, doxorubicin hydrochloride IV, and vincristine IV on day 1 and oral prednisone on days 1-5. Patients also receive alemtuzumab subcutaneously (SC) 1-3 times a week for up to 6 doses per course. Treatment repeats every 3 weeks for up to 8 courses in the absence of disease progression or unacceptable toxicity.
Patients undergo blood collection at baseline, periodically during study treatment, and after completion of study therapy for pharmacokinetics and other correlative studies to monitor cellular immunity. Blood samples are examined by polymerase chain reaction to detect cytomegalovirus antigen and to monitor Epstein-Barr virus copy number. Samples are also analyzed by flow cytometry to quantify circulating B- and T-cells, NK-cells, monocytes, and dendritic-cells.
After completion of study therapy, patients are followed every 3 months for the first year, every 6 months for the second year, and then yearly thereafter.
연구 유형
등록 (예상)
단계
- 1단계
연락처 및 위치
연구 장소
-
-
England
-
Leeds, England, 영국, LS1 3EX
- 모병
- Leeds General Infirmary
-
연락하다:
- Contact Person
- 전화번호: 44-113-392-3766
-
London, England, 영국, SW3 6JJ
- 모병
- Royal Marsden - London
-
연락하다:
- Contact Person
- 전화번호: 44-20-7352-8171
-
London, England, 영국, SE5 9RS
- 모병
- King's College Hospital
-
연락하다:
- Contact Person
- 전화번호: 44-20-3299-9000
-
Manchester, England, 영국, M20 4BX
- 모병
- Christie Hospital
-
연락하다:
- Contact Person
- 전화번호: 44-161-446-8565
-
Torbay Devon, England, 영국, TQ2 7AA
- 모병
- Torbay Hospital
-
연락하다:
- Contact Person
- 전화번호: 44-180-365-5260
-
-
참여기준
자격 기준
공부할 수 있는 나이
건강한 자원 봉사자를 받아들입니다
연구 대상 성별
설명
DISEASE CHARACTERISTICS:
Diagnosis of peripheral T-cell lymphoma (PTCL), including the following subtypes:
- PTCL not otherwise specified
- Angioimmunoblastic T-cell lymphoma
- Anaplastic lymphoma kinase-negative anaplastic large cell lymphoma
- Intestinal T-cell lymphoma
- Bulky stage IA and stages IB-IV disease (Ann Arbor staging system)
- Expression of CD52 by the tumor
- Measurable or evaluable disease
- No anaplastic lymphoma kinase-positive anaplastic large-cell lymphoma
- No CNS involvement with non-Hodgkin lymphoma
PATIENT CHARACTERISTICS:
- WHO performance status 0-2
- No presence of other serious, uncontrolled medical conditions
- No significant anthracycline-related cardiac impairment
- LVEF ≥ 50%
- Creatinine ≤ 1.5 mg/dL
- Bilirubin ≤ 2 times normal value unless due to disease
- Not pregnant or nursing
- Fertile patients must use effective barrier contraception during and for 1 month after completion of study treatment
- No previous malignancy except adequately treated nonmelanoma skin cancer or cervical intraepithelial neoplasia
No positive serology or non-consenting to test for any of the following:
- HIV
- Hepatitis B or C
- Human T-lymphotropic virus type 1 (HTLV-1)
PRIOR CONCURRENT THERAPY:
- No prior cytotoxic chemotherapy
- Prior radiotherapy may be allowed at the trial coordinator's discretion
- Concurrent consolidation radiotherapy may be given at the clinician's discretion
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
- 주 목적: 치료
- 마스킹: 없음(오픈 라벨)
연구는 무엇을 측정합니까?
주요 결과 측정
결과 측정 |
|---|
|
Immediate toxicity (incidence of infusion-related reactions)
|
|
Hematopoietic toxicity (number of cycles of therapy associated with neutrophils < 0.5e9/L or platelets < 50e9/L)
|
|
Incidence of infection (number of days with fever ≥ 38 degrees C, days of intravenous antibiotics, number of inpatient days, number of episodes of cytomegalovirus reactivation)
|
2차 결과 측정
결과 측정 |
|---|
|
상대 선량 강도
|
|
Disease response (remission rate [complete response and partial response])
|
|
Disease outcome (time to progression and overall survival at 2 years from completion of therapy)
|
|
Immune reconstitution (time to recover peripheral blood CD4 count to 0.2 e9/L)
|
|
Pharmacokinetics assessment of alemtuzumab trough levels before each cycle of treatment
|
|
Epstein-Barr virus copy number (measured retrospectively)
|
공동 작업자 및 조사자
수사관
- 연구 의자: Roderick Johnson, MD, Leeds General Infirmary
간행물 및 유용한 링크
연구 기록 날짜
연구 주요 날짜
연구 시작
기본 완료 (예상)
연구 등록 날짜
최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (추정)
연구 기록 업데이트
마지막 업데이트 게시됨 (추정)
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
추가 정보
이 연구와 관련된 용어
키워드
추가 관련 MeSH 약관
- 소화기계 질환
- 면역계 질환
- 조직학적 유형에 따른 신생물
- 신생물
- 림프 증식 장애
- 림프계 질환
- 면역증식성 장애
- 림프종, 비호지킨
- 부위별 신생물
- 위장관 신생물
- 소화계 신생물
- 위장병
- 장 질환
- 림프종
- 림프종, T 세포
- 림프종, T 세포, 말초
- 장 신생물
- 약물의 생리적 효과
- 약리작용의 분자기전
- 효소 억제제
- 항염증제
- 항류마티스제
- 항종양제
- 면역억제제
- 면역학적 요인
- 튜불린 조절제
- 항유사분열제
- 유사분열 조절제
- 글루코 코르티코이드
- 호르몬
- 호르몬, 호르몬 대체물 및 호르몬 길항제
- 항종양제, 호르몬
- 항종양제, 알킬화제
- 알킬화제
- 골수 파괴 작용제
- 항종양제, 식물성
- 토포이소머라제 II 억제제
- 토포이소머라제 억제제
- 항종양제, 면역학적
- 항생제, 항종양제
- 프레드니솔론
- 사이클로포스파마이드
- 독소루비신
- 리포솜 독소루비신
- 빈크리스틴
- 알렘투주맙
기타 연구 ID 번호
- CDR0000576439
- UCL-BRD/05/170
- EU-20785
- EUDRACT-2006-000365-11
- CTA 21786/0201/001-0001
- CRUK-UCL-BRD/05/170-CHOP-CAMPA
- UCL-CHOP-CAMPATH
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .